Academic article

• Vere Rose Megens; Peter Wessel Strandhagen; Erik Magnus Berntsen et al. (2026). The clinical Alzheimer's disease spectrum classified in the A/T/N framework with 18F-Flutemetamol-Centiloid, 18F-MK-6240-CenTauR, and 18F-FDG-AD metaROI: a multicenter memory clinic observational study. (external link)
• Stephanie Knudtzon; Bjørn-Eivind Kirsebom; Lene Pålhaugen et al. (2026). Genotype–phenotype interaction in Alzheimer's disease immune activation. (external link)
• Ingvild Vøllo Eliassen; Bjørn-Eivind Kirsebom; Knut Waterloo et al. (2025). Pathological biomarkers for Alzheimer’s disease in cognitively unimpaired individuals are not associated with cognitive decline at two-year follow-up. (external link)
• Bjørn-Eivind Kirsebom; Johanna Nilsson; Ellen Vromen et al. (2025). Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways. (external link)
• Grit Richter; Bjørn-Eivind Kirsebom; Jonas Alexander Jarholm et al. (2025). Comparison of CSF neurofilament light chain and total tau as neurodegeneration markers: Associations with synaptic markers and cognitive outcomes. (external link)
• Fernando Gonzalez-Ortiz; Bjørn-Eivind Kirsebom; Yara Yakoub et al. (2025). Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease. (external link)
• Lucy L. Gibson; Ragnhild Eide Skogseth; Tibor Hortobagyi et al. (2025). Clinical Evolution of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies in a Post-Mortem Cohort. (external link)
• Simon Ulvenes Kverneng; Kjersti Eline Stige; Haakon Berven et al. (2025). Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease. (external link)
• Stephanie Knudtzon; Kaja Nordengen; Lene Pålhaugen et al. (2025). Sexual dimorphisms in innate immune activation markers in predementia Alzheimer’s disease. (external link)
• Bjørn-Eivind Kirsebom; Fernando Gonzalez-Ortiz; Sinthujah Vigneswaran et al. (2025). Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity. (external link)
• Mathilde Suhr Hemminghyth; Monica Haraldseid Breitve; Luiza Chwiszczuk et al. (2025). Demographically unadjusted cognitive test scores may enhance the validity of mild cognitive impairment as a dementia prodrome. (external link)
• Irit Titlestad; Kristoffer Haugarvoll; Stein-Erik Hafstad Solvang et al. (2024). Delirium is frequently underdiagnosed among older hospitalised patients despite available information in hospital medical records. (external link)
• Fernando Gonzalez-Ortiz; Bjørn-Eivind Seljelid Kirsebom; José Contador et al. (2024). Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. (external link)
• Camilla Christina Pedersen; Anastasia Ushakova; Ragnhild Eide Skogseth et al. (2023). Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders. (external link)
• Giil Lasse Melvær; Stein-Erik Hafstad Solvang; Malin Melvaer Giil et al. (2019). Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. (external link)
• Ragnhild Eide Skogseth; Tibor Hortobágyi; Hogne Sønnesyn et al. (2017). Accuracy of clinical diagnosis of dementia with lewy bodies versus neuropathology. (external link)
• Ragnhild Eide Skogseth; Kolbjørn S Brønnick; Joana Braga Pereira et al. (2015). Associations between cerebrospinal fluid biomarkers and cognition in early Untreated Parkinson's Disease. (external link)
• Ezra Mulugeta; Elisabet Londos; Clive Ballard et al. (2011). CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies. (external link)
• Dag Aarsland; Arvid Rongve; Sabine Piepenstock Nore et al. (2008). Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria. (external link)
• Ragnhild Eide Skogseth; Ezra Mulugeta; Clive Ballard et al. (2008). Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. (external link)

Academic literature review

• Arvid Rongve; Hogne Sønnesyn; Ragnhild Eide Skogseth et al. (2016). Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. (external link)
• Ragnhild Eide Skogseth; Tormod Fladby; Ezra Mulugeta et al. (2011). Biomarkører i spinalvæske ved demens. (external link)

Conference lecture

• Håvard Kjesbu Skjellegrind; Ragnhild Eide Skogseth (2026). En norsk RCT for zoster-vaksine som demensforebygging - er det mulig?. (external link)

Doctoral thesis (PhD)

• Ragnhild Eide Skogseth; Dag Aarsland; Nils Erik Gilhus et al. (2019). Biomarker and pathology studies in neurodegenerative cognitive impairment. (external link)

Other presentation

• Ragnhild Eide Skogseth; Silje Haukenes Stavestrand; Inger Hilde Nordhus (2026). Håp eller håpløshet? Tre forskere om aldring. (external link)

Professional article

• Luiza Chwiszczuk; Monica Haraldseid Breitve; Bjørn-Eivind Kirsebom et al. (2023). The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. (external link)

Study protocol

• Marcela Lichtensztejn; Anja-Xiaoxing Cui; Monika Geretsegger et al. (2025). Memory for Music (M4M) protocol for an international randomised controlled trial: effects of individual intensive musical training based on singing in non-musicians with Alzheimer’s disease. (external link)
• Marcela Lichtensztejn; Anja-Xiaoxing Cui; Monika Geretsegger et al. (2024). Memory for Music (M4M) protocol for an international randomized controlled trial: Effects of individual intensive musical training based on singing in non-musicians with Alzheimer’s disease. (external link)

See a complete overview of publications in NVA.